Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2015, Pages

  van der Heijden, Esther ^a   Lopes, Alberto D ^b   Bryant, Andrew ^c   Bekkers, Ruud ^a   Galaal, Khadra ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL CORNWALL HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY; CANCER RECURRENCE; COLPOSCOPY; CONSERVATIVE TREATMENT; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GENOTYPING TECHNIQUE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LARGE LOOP EXCISION OF THE TRANSFORMATION ZONE; MORBIDITY; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERUS SURGERY; VIRUS EXAMINATION; WART VIRUS; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; MINIMAL RESIDUAL DISEASE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84969309535     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010757.pub2     Document Type: Review

References (73)

1. Aerssens A, Claeys P, Beerens E, Garcia A, Weyers S, Van Renterghem L, et al. Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia. Cytopathology 2009;20(1):27-35.
2. Almog B, Gamzu R, Kuperminc MJ, Levin I, Fainaru O, Niv J, et al. Human papilloma virus testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia. Gynecologic Oncology 2003;88(3):345-50.
3. Alonso I, Torne A, Puig-Tintore LM, Esteve R, Quinto L, Campo E, et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecologic Oncology 2006;103(2):631-6.
4. Bae JH, Kim CJ, Park TC, Namkoong SE, Park JS. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Internal Journal of Gynecological Cancer 2007;17(6):1271-7.
5. Bar-Am A, Gamzu R, Levin I, Fainaru O, Niv J, Almog B. Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up. Gynecologic Oncology 2003;91(1):149-53.
6. Bekkers RL, Melchers WJ, Bakkers JM, Hanselaar AG, Quint WG, Boonstra H, et al. The role of genotype-specific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia. International Journal of Cancer 2002;102(2):148-51.
7. Bais AG, Eijkemans MJ, Rebolj M, Snijders PJ, Verheijen RH, van M, et al. Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. International Journal of Cancer 2009;124(4):889-95.
8. Bollen LJM, Tjong-A-Hung SP, Van Velden J, Mol BW, Ten FWJ, Ter J, et al. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecologic Oncology 1999;72(2):199-201.
9. Brismar S, Johansson B, Borjesson M, Arbyn M, Andersson S. Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. American Journal of Obstetrics and Gynecology 2009;201(1):17.e1-8.
10. Castle PE, Kreimer AR, Wacholder S, Wheeler CM, Koutsky LA, Rydzak G, et al. Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections. Journal of Infectious Disease 2009;199(11):1612-20.
11. Cecchini S, Carozzi F, Confortini M, Zappa M, Ciatto S. Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure. Tumori 2004;90(2):225-8.
12. Chao A, Lin CT, Hsueh S, Chou HH, Chang TC, Chen MY, et al. Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization. American Journal of Obstetrics and Gynecology 2004;190(4):1046-51.
13. Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M, et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecologic Oncology 2003;90(2):358-65.
14. Dogan NU, Salman MC, Yuce K. The role of HPV DNA testing in the follow-up of cervical intraepithelial neoplasia after loop electrosurgical excision procedure. Archives of Gynecology and Obstetrics 2011;283(4):871-7.
15. Fambrini M, Penna C, Pieralli A, Bussani C, Fallani MG, Andersson KL, et al. PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia. Gynecologic Oncology 2008;109(1):59-64.
16. Houfflin Debarge V, Collinet P, Vinatier D, Ego A, Dewilde A, Borman F, et al. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. Gynecologic Oncology 2003;90(3):587-92.
17. Jancar N, Rakar S, Poljak M, Fujs K, Kocjan BJ, Vrtacnik-Bokal E. Efficiency of three surgical procedures in eliminating high-risk human papillomavirus infection in women with precancerous cervical lesions. European Journal of Gynaecological Oncology 2006;27(3):239-42.
18. Jeong NH, Lee NW, Kim HJ, Kim T, Lee KW. High-risk human papillomavirus testing for monitoring patients treated for high-grade cervical intraepithelial neoplasia. The Journal of Obstetrics and Gynaecology Research 2009;35(4):706-11.
19. Jones J, Saleem A, Rai N, Shylasree TS, Ashman S, Gregory K, et al. Human papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: the importance of a persistent viral infection. Journal of Clinical Virology 2011;52(2):88-92.
20. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. The Lancet Oncology 2011;12(5):441-50.
21. Korolenkova LI. [Value of HPV (hybrid capture 2) testing for assessing the effectiveness of conservative surgical treatment in CIN2-3/carcinoma in situ and microinvasive cervical cancer]. Voprosy Onkologii 2011;57(3):322-6.
22. Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiology Biomarker and Prevention 2006;15(5):908-14.
23. Kucera E, Sliutz G, Czerwenka K, Breitenecker G, Leodolter S, Reinthaller A. Is high-risk human papillomavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone?. European Journal of Obstetrics Gynecology and Reproductive Biology 2001;100(1):72-6.
24. Leguevaque P, Motton S, Decharme A, Soule-Tholy M, Escourrou G, Hoff J. Predictors of recurrence in high-grade cervical lesions and a plan of management. European Journal of Surgical Oncology 2010;36(11):1073-9.
25. Mikolajczyk K, Kedzia W, Zaba R, Silny W. Evaluation of HPV DNA HR assay in females as a marker of recurrent disease following treatment of cervical intraepithelial neoplasia. Ginekologia Polska 2011;82(9):670-4.
26. Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence?. Gynecologic Oncology 2000;79(2):294-9.
27. Nagai N, Mukai K, Oshita T, Shiroyama Y, Ohama K. Human papillomavirus DNA status after loop excision for cervical intraepithelial neoplasia grade III: a prospective study. International Journal of Molecular Medicine 2004;13(4):589-93.
28. Prato B, Ghelardi A, Gadducci A, Marchetti I, Di Cristofano C, Di Coscio G, et al. Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. International Journal of Gynecological Cancer 2008;18(1):90-4.
29. Sarian LO, Derchain SF, Pitta Dda R, Morais SS, Rabelo-Santos SH. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). Journal of Clinical Virology 2004;31(4):270-4.
30. Sarian LO, Derchain SFM, Andrade LAA, Tambascia J, Morais SS, Syrjanen KJ. HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia. Gynecologic Oncology 2004;94(1):181-6.
31. Smart OC, Sykes P, Macnab H, Jennings L. Testing for high risk human papilloma virus in the initial follow-up of women treated for high-grade squamous intraepithelial lesions. Australian and New Zealand Journal of Obstetrics and Gynaecology 2010;50(2):164-7.
32. Tachezy R, Mikyskova I, Ludvikova V, Rob L, Kucera T, Slavik V, et al. Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies. European Journal of Clinical Microbiology and Infectious Diseases 2006;25(8):492-500.
33. Takac I. Human papillomavirus infection in patients with residual or recurrent cervical intraepithelial neoplasia. Tumori 2008;94(1):83-6.
34. Taylor S, Wang C, Wright TC, Denny L, Kuhn L. A comparison of human papillomavirus testing of clinician-collected and self-collected samples during follow-up after screen-and-treat. International Journal of Cancer 2011;129(4):879-86.
35. Trope A, Jonassen CM, Sjoborg KD, Nygard M, Dahl FA, Alfsen GC, et al. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia. Gynecologic Oncology 2011;123(2):257-62.
36. Valasoulis G, Koliopoulos G, Founta C, Kyrgiou M, Tsoumpou I, Valari O, et al. Alterations in human papillomavirus-related biomarkers after treatment of cervical intraepithelial neoplasia. Gynecologic Oncology 2011;121(1):43-8.
37. Van Ham MAPC, Van D, Bekkers RLM, Bulten J, Melchers WJG, Massuger LFAG. High-risk HPV presence in cervical specimens after a large loop excision of the cervical transformation zone: significance of newly detected hr-HPV genotypes. Journal of Medical Virology 2007;79(3):314-9.
38. Venturoli S, Ambretti S, Cricca M, Leo E, Costa S, Musiani M, et al. Correlation of high-risk human papillomavirus genotypes: persistence and risk of residual or recurrent cervical disease after surgical treatment. Journal of Medical Virology 2008;80(8):1434-40.
39. Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG 2006;113(11):1303-7.
40. Young TK, Lee JM, Hur SY, Cho CH, Kim YT, Seung CK, et al. Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasia. International Journal of Cancer 2010;126(8):1903-9.
41. Zielinski GD, Rozendaal L, Voorhorst FJ, Berkhof J, Snijders PJ, Risse EJ, et al. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. Gynecologic Oncology 2003;91(1):67-73.
42. Alvarez RD, Helm CW, Edwards RP, Naumann RW, Partridge EE, Shingleton HM, et al. Prospective randomized trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia. Gynecologic Oncology 1994;52(2):175-9.
43. Arbyn M, Herbert A, Schenck U, Nieminen P, Jordan J, Mcgoogan E, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007;18:133-9.
44. Brisson J, Morin C, Fortier M, Roy M, Bouchard C, Leclerc J, et al. Risk factors for cervical intraepithelial neoplasia: differences between low- and high-grade lesions. American Journal of Epidemiology 1994;140(8):700-10.
45. Brockmeyer AD, Wright JD, Gao F, Powell MA. Persistent and recurrent cervical dysplasia after loop electrosurgical excision procedure. American Journal of Obstetrics and Gynecology 2005;192(5):1379-81.
46. Brown JV, Peters WA, Corwin DJ. Invasive carcinoma after cone biopsy for cervical intraepithelial neoplasia. Gynecologic Oncology 1991;40(1):25-8.
47. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
48. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
49. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al. and the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94: results and commentary. Annals of Oncology 2003;14 (Suppl 5):v61-v118.
50. Fallani MG, Penna C, Marchionni M, Bussani C, Pieralli A, Andersson KL, et al. Prognostic significance of high-risk HPV persistence after laser CO2 conization for high-grade CIN: a prospective clinical study. European Journal of Gynaecological Oncology 2008;29(4):378-82.
51. Franco EL. Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. Journal of the National Cancer Institute. Monographs 2003;31:89-96.
52. Galaal K, Bryant A, Deane KH, Al-Khaduri M, Lopes AD. Interventions for reducing anxiety in women undergoing colposcopy. Cochrane Database of Systematic Reviews 2011, Issue CD006013. [DOI:10.1002/14651858.CD006013.pub3 ]
53. Ghaem-Maghami S, Sagi S, Majeed G, Soutter WP. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. Lancet Oncology 2007;8(11):985-93.
54. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer incidence and mortality worldwide. IARC CancerBase No. 10 [Internet]. Lyon, France, 2010; Vol. International Agency for Research on Cancer:http://globocan.iarc.fr.
55. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
56. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. www.cochrane-handbook.org, The Cochrane Collaboration, 2011.
57. Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. International Journal of Cancer 2003;107(5):811-6.
58. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Medicine 2008;5(1):e20. doi:10.1371/journal. pmed.0050020.
59. Jain S, Tseng CJ, Horng SG, Soongy K, Pao CC. Negative predictive value of human papillomavirus test following conization of the cervix uteri. Gynecologic Oncology 2001;82(1):177-80.
60. Kocken M, Uijterwaal MH, de Vries AL, Berkhof J, Ket JC, Helmerhorst TJ, et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecologic Oncology 2012;125(2):500-7.
61. Luesley D, Leeson S. Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme. NHSCSP Publication No. 20. 2nd Edition. Sheffield: NHSCSP, 2010.
62. Lörincz AT. Screening for cervical cancer: new alternatives and research. Salud Publica Mex 2003;45(Suppl 3):S376-87.
63. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncology 2008;9(5):425-34.
64. Mitchell MF, Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris H, Silva E. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstetrics and Gynecology 1998;92(5):737-44.
65. Nam K, Chung S, Kim J, Jeon S, Bae D. Factors associated with HPV persistence after conization in patients with negative margins. Journal of Gynecological Oncology 2009;20(2):91-5.
66. NHSCSP. Evaluation of sentinel sites for HPV triage and test of Cure, 2011. http://www.cancerscreening.nhs.uk/cervical/sentinelfinalreport.pdf (accessed 24 September 2012).
67. Nobbenhuis MA, Meijer CJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Risse EK, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. British Journal of Cancer 2001;84(6):796-801.
68. Paraskevaidis E, Lolis ED, Koliopoulos G, Alamanos Y, Fotiou S, Kitchener HC. Cervical intraepithelial neoplasia outcomes after large loop excision with clear margins. Obstetrics and Gynecology 2000;95:828-31.
69. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
70. Pinto AP, Crum CP. Natural history of cervical neoplasia: defining progression and its consequence. Clinical Obstetrics and Gynecology 2000;43(2):352-62.
71. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. Journal of the National Cancer Institute 1993;85(12):958-64.
72. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. International Journal of Cancer 2006;118(8):2048-55.
73. Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349(9057):978-80.